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Abstract
Genetically engineered mouse models (GEMMs) have dramatically improved our understanding 
of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene 
expression and targeting of the host is almost impossible using conventional Cre-loxP–based 
models. We have developed an inducible dual-recombinase system by combining flippase-FRT 
(Flp-FRT) and Cre-loxP recombination technologies to improve GEMMs of pancreatic cancer. 
This enables investigation of multistep carcinogenesis, genetic manipulation of tumor 
subpopulations (such as cancer stem cells), selective targeting of the tumor microenvironment and 
genetic validation of therapeutic targets in autochthonous tumors on a genome-wide scale. As a 
proof of concept, we performed tumor cell–autonomous and nonautonomous targeting, 
recapitulated hallmarks of human multistep carcinogenesis, validated genetic therapy by 3-
phosphoinositide-dependent protein kinase inactivation as well as cancer cell depletion and show 
that mast cells in the tumor microenvironment, which had been thought to be key oncogenic 
players, are dispensable for tumor formation.
Pancreatic ductal adenocarcinoma (PDAC) is a fearsome disease, with a mortality rate >95% 
that has remained unchanged for decades1.
GEMMs that faithfully recapitulate the histological, molecular, genetic and clinical 
hallmarks of human PDAC have been developed2–5. All are based on pancreatic expression 
of oncogenic KrasG12D or KrasG12V, which induce pancreatic intraepithelial neoplasias 
(PanINs) that progress to aggressive metastatic PDAC2–4,6–9. These GEMMs have 
elucidated the natural biology of pancreatic cancer, revealed potential diagnostic and 
therapeutic targets10,11 and highlighted the importance of the tumor stroma for PDAC 
maintenance, immune evasion and drug resistance5,12–14.
However, classical Cre-loxP–based GEMMs rely on a single Cre-mediated recombination 
step to activate mutant Kras expression and do not allow genetic modeling and manipulation 
of sequential multistep tumorigenesis and tumor heterogeneity, which are important 
hallmarks of the disease. A single-step approach does not enable genetic validation of 
possible targets by blocking PanIN progression or treating established PDAC, nor does it 
enable genetic investigation of resistance mechanisms or manipulation of the tumor 
microenvironment.
We addressed these limitations by generating a ‘next-generation’ mouse model that allows 
controlled independent or sequential manipulation of genes involved in the development and 
maintenance of PDAC.
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RESULTS
Sequential genetic manipulation of the pancreas
To create a dual-recombinase system (DRS), we generated transgenic mice expressing 
Flprecombinase directed by the mouse Pdx1 promoter15 (Pdx1-Flp; Supplementary Fig. 
1a,b). A Flp-activated alkaline phosphatase reporter allele (FSF-R26hpAP/+) revealed 
recombination in pancreatic islets, ducts and acini, and we observed extra-pancreatic 
recombination in bile duct, duodenum and stomach, paralleling established Pdx1-Cre 
lines2,15 (Supplementary Fig. 1c–f and Supplementary Table 1).
To manipulate Flp-recombined cells sequentially using Cre, we generated a latent 
tamoxifen-inducible allele (CreERT2) silenced by an FRT-stop-FRT (FSF) cassette under the 
control of the CAG promoter as a Rosa26 knock-in (FSF-R26CAG-CreERT2/+; 
Supplementary Fig. 2a, b). To activate CreERT2 expression and monitor tamoxifen-
induced CreERT2-mediated recombination in the Flp-lineage, we used the Pdx1-Flp line 
together with a dual-fluorescent tdTomato-EGFP-Cre reporter (R26mT-mG) that switches 
expression from tdTomato to EGFP after Cre recombination (Supplementary Fig. 2c, d). 
Tamoxifen treatment induced EGFP expression in pancreatic acini, ducts and islets; stromal 
cells remained unrecombined (Supplementary Fig. 2d). Immunohistochemistry confirmed 
colocalization of EGFP with markers for acini (α-amylase), ducts (CK19) and islets 
(insulin); we observed sporadic extrapancreatic recombination in stomach, duodenum and 
bile duct (Supplementary Fig. 2c–f and data not shown). There was no evidence of 
recombination in the absence of tamoxifen, excluding leaky Cre activity in this system.
Tamoxifen-inducible genetic manipulation of the whole animal
Toxicity in non-neoplastic cells is a major limitation of many current drugs. It is thus 
important to evaluate the consequences of inactivating a specific therapeutic target or 
pathway in whole animals. To mimic drug treatment and reveal potential toxic side effects, 
we generated a CreERT2 deleter model, R26CAG-CreERT2, which ubiquitously expresses 
CreERT2 (Supplementary Fig. 3a).
High-dose tamoxifen treatment resulted in efficient Cre recombination of the R26mT-mG 
reporter in various tissues, at low dose in just a few cells, whereas untreated mice showed 
none (Supplementary Figs. 3b, c and 4).
Activation of oncogenic KrasG12D induces metastatic PDAC
To achieve conditional activation of oncogenic Kras in the Pdx1-Flp lineage, we generated a 
FSF-silenced latent KrasG12D knock-in allele (FSF-KrasG12D/+; Supplementary Fig. 5a, 
b). KrasG12D expression from the endogenous promoter in Pdx1-Flp-FSF-KrasG12D/+ 
(termed KF) mice induced PanIN precursor lesions and PDAC originating from Pdx1-Flp–
recombined cells, as confirmed by the FSF-R26hpAP reporter (Fig. 1a, b).
The KF and the classical Pdx1-Cre;LSL-KrasG12D/+ (termed KC)2 mice showed similar 
patterns of PanIN progression and PDAC formation (Fig. 1a, c, d). Tumor latency, 
morphology, survival time and rates of metastasis were nearly identical (Fig. 1d and 
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Supplementary Fig 5c–e). PDAC in KF and KC mice were histopathologically 
indistinguishable, showing the full disease spectrum, from well-differentiated to 
undifferentiated tumors and typical liver and lung metastasis (Fig. 1a,b, Supplementary 
Fig. 5c–e and data not shown). Both KF and KC models thus faithfully recapitulate human 
PDAC2,12.
To accelerate PDAC formation, we generated KPF mice, in which the tumor suppressor p53 
is inactivated through usage of an FRT-flanked Trp53 allele (Trp53frt) (Supplementary Fig. 
6). We also crossed the KF model with a mouse line that lacks p53 in the whole body 
(Trp53Δ) and compared PDAC formation, metastasis rates and survival with the classical 
KPC (Pdx1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+) model, which carries a p53R172H gain 
of function mutation 12,16. Again, tumors were histopathologically indistinguishable, 
revealing the full spectrum of human PDAC, from well- to poorly-differentiated and 
anaplastic tumors (Supplementary Fig. 6a–c). Median survival times and rates of 
metastasis were very similar (Supplementary Fig. 6a–e), and the number of metastatic 
lesions varied between one and several dozen in all models.
To assess extrapancreatic tumor development, we analyzed KF mice and observed sporadic 
noninvasive skin and bile duct papillomas and serrated duodenal adenomas in <10% of KF 
mice (Fig. 1e); by contrast, the incidence of skin papillomas is as high as 80% in KC mice2. 
Notably, we observed no extrapancreatic invasive carcinomas. Overall, the extrapancreatic 
pathologies of KF mice resembled those of the KC model2 but occurred at much lower 
frequencies. Inactivation of p53 did not affect the frequency or invasiveness of 
extrapancreatic tumors, probably owing to the rapidity of PDAC development 
(Supplementary Fig. 6a–c).
These results indicate that the KF and KPF models phenocopy the widely used KC and KPC 
models2,16 and may provide an improvement by reducing unwanted extrapancreatic tumor 
development.
Sequential genetic manipulation of PanIN lesions and PDAC
KF mice develop PanIN and PDAC. To target and manipulate these lesions at a chosen time 
point using Cre-loxP, we crossed the FSF-R26CAG-CreERT2 allele into KF mice and used the 
R26mT-mG-Cre reporter to visualize the secondary genetic alteration (Fig. 2a). Tamoxifen-
activation of CreERT2 resulted in efficient excision of tdTomato and induction of EGFP in 
PanIN lesions in vivo (Fig. 2b). Tumor stroma showed no evidence of recombination. No 
recombination was detected in vehicle-treated mice (Fig. 2b and data not shown), excluding 
leaky Cre activity or spontaneous recombination events in this system.
To investigate whether our model provides the opportunity to recapitulate crucial aspects of 
human multistep carcinogenesis, we uncoupled temporal activation of oncogenic Kras from 
elimination of p53. We activated CreERT2 by tamoxifen treatment in 2-month-old Pdx1-
Flp;FSF-KrasG12D/+;FSF-R26CAG-CreERT2/+ mice with and without loxP-flanked (floxed) 
Trp53 (Fig. 2c,d) and analyzed tumor development 1 month later. Inactivation of p53 in a 
stage-specific fashion induced rapid formation of multifocal PDAC. Histopathology 
revealed tumors that were well-to-moderately differentiated or undifferentiated. Untreated 
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Pdx1-Flp;FSF-KrasG12D/+;FSF-R26CAG-CreERT2/+;Trp53lox/lox littermate controls and 
tamoxifen-treated mice lacking the floxed Trp53 showed only PanIN lesions (Fig. 2d and 
Supplementary Fig. 7b).
To investigate whether gene expression can be modulated in a stage-specific manner, 
including in established PDAC, we used a Cre-activatable lacZ reporter line (LSL-
R26Tva-i-lacZ)4. CreERT2 activation by tamoxifen resulted in lacZ expression in PanIN and 
PDAC in vivo (Fig. 2e and Supplementary Fig. 8a–c). Again, the tumor stroma showed no 
apparent recombination events. Importantly, we observed no difference in recombination 
efficacy between stroma-rich, well-differentiated tumors and undifferentiated PDAC lacking 
desmoplasia (Fig. 2e and Supplementary Fig. 8c).
To manipulate PDAC in vitro, we isolated and cultured tumor cells from tamoxifen-naive 
Pdx1-Flp;FSF-KrasG12D/+;FSF-R26CAG-CreERT2 mice carrying the R26mT-mG-Cre reporter. 
Administration of tamoxifen resulted in EGFP expression within 24 h (Supplementary Fig. 
8d).
The DRS enables validation of therapeutic targets
To test whether the DRS can be used to define and validate therapeutic targets in vivo, we 
crossed Pdx1-Flp;FSF-KrasG12D/+;FSF-R26CAG-CreERT2/+ mice with conditional floxed 
Pdpk1 (encoding 3-phosphoinositide-dependent protein kinase 1 (Pdpk1)) knockout mice17. 
This enables tamoxifen-mediated deletion of Pdpk1 in KrasG12D-induced PanIN (Fig. 3a,b). 
Pdpk1 is an important downstream effector of phosphoinositide 3-kinase and essential for 
KrasG12D-induced PDAC initiation17. However, it remains unclear whether Pdpk1 is also 
necessary for PDAC progression. To inactivate floxed Pdpk1 (Pdpk1lox/lox) in a time- and 
stage-controlled fashion after PanIN formation, we activated CreERT2 in 3-month-old Pdx1-
Flp;FSFKrasG12D/+;FSF-R26CAG-CreERT2;Pdpk1lox/lox conditional knockout animals and 
Pdx1-Flp;FSFKrasG12D/+;FSF-R26CAG-CreERT2;Pdpk1lox/+ controls and analyzed pancreata 
in mice at age 9 months. Inactivation of both Pdpk1 alleles resulted in macroscopically 
normal pancreata with normal size and weight, whereas tamoxifen-treated heterozygous 
Pdpk1lox/+ controls showed increased pancreatic weight and size and macroscopic signs of 
tumor development (Fig. 3b). Pdpk1-deleted mice retained normal pancreatic tissue 
architecture and showed only sporadic PanINs, whereas pancreata from control mice were 
nearly completely replaced by tumorous tissue owing to induction of low- and high-grade 
PanIN lesions (Fig. 3c,d). Thus, Pdpk1 ablation in PanIN-bearing animals blocked tumor 
progression almost completely. Notably, the few PanINs that were present in tamoxifen-
treated Pdpk1lox/lox mice expressed Pdpk1 (Fig. 3c), suggesting incomplete recombination 
of the Pdpk1 locus. This was confirmed by laser-capture microdissection and genotyping 
PCR, which showed the intact floxed Pdpk1 band (Fig. 3e). Thus, KrasG12D-driven PDAC 
progression depends on intact Pdpk1 expression.
To investigate whether the DRS can be used to validate therapeutic targets in established 
invasive PDAC in vitro and in vivo, we crossed Pdx1-Flp;FSF-
KrasG12D/+;FSFR26CAG-CreERT2 mice with conditional LSL-R26DTA/+ mice, which carry a 
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latent DTA allele (encoding diphtheria toxin A) (Fig. 3f). This enables depletion of all Flp-
recombined cells as a proof of concept.
Tamoxifen-mediated Cre activation and DTA expression in cultured PDAC cells led to 
extensive cell death and depletion of PDAC cells in vitro (Supplementary Fig. 9a–c). To 
investigate the feasibility of PDAC depletion in vivo, we monitored PDAC formation in 
Pdx1-Flp;FSF-KrasG12D/+;FSF-R26CAG-CreERT2 mice with (DTA) or without (control) the 
LSLR26DTA allele by high-resolution ultrasound. Mice with established tumors of 
comparable size were then enrolled and treated with tamoxifen to activate Cre and express 
DTA. Tamoxifen-mediated DTA induction led to rapid regression of tumor volume, whereas 
control mice showed rapid disease progression (Fig. 3f–h and Supplementary Fig. 9d).
After 7–14 d tamoxifen treatment, mice in the conditional DTA cohort showed tumor 
regression, and pancreatic masses were rarely detectable by ultrasound, macroscopic 
pathological examination or histopathology (Fig. 3g–j and Supplementary Fig. 9d–f). 
Other pancreata of the DTA cohort displayed some residual small tumor nodules, with 
histopathological signs of intact tumor tissue (Supplementary Fig. 9e,f). As we expected, 
tamoxifen treatment resulted in pancreatitis and pancreatic atrophy due to DTA-mediated 
cell depletion of both neoplastic and normal pancreatic tissue (Fig. 3i,j and Supplementary 
Fig. 9e,f). Histopathological analysis and abnormally elevated serum lipase concentrations 
of tamoxifen-treated Pdx1-Flp;FSF-R26CAG-CreERT2;LSL-R26DTA mice without the 
oncogenic KrasG12D allele confirmed pancreatitis induction by DTA expression. 
Tamoxifen-treated control mice showed normal pancreatic histology, no signs of 
inflammation or atrophy and normal serum lipase levels (Supplementary Fig. 9g,h).
To investigate whether tamoxifen or activation of CreERT2 itself affects PDAC growth, we 
also treated Pdx1-Flp;FSF-KrasG12D/+;FSF-R26CAG-CreERT2 tumor cells and mice with the 
FSF-R26CAG-CreERT2 allele but not the latent DTA allele with tamoxifen. These cells and 
tumors continued to grow after treatment (Fig. 3g,h and Supplementary Fig. 9b,c). The 
effects thus depend on DTA expression and not Cre recombinase toxicity18.
Functional analysis of cell populations within the tumor microenvironment — mast cells 
are dispensable for PDAC initiation.]
Mast cells link the innate and adaptive immune systems and have been implicated in tumor 
initiation, progression and metastasis of various tumor entities19. Our data show mast cell 
infiltration in human PDAC and in KC mice (Supplementary Fig. 10a–e). However, the 
pro- or antitumorigenic function of mast cells is controversial20–22.
We used the DRS method to evaluate the contribution of mast cells to pancreatic 
carcinogenesis. To deplete mast cells in vivo, we used the mast cell–deficient Cpa3Cre/+ 
line, which is not based on Kit hypomorphism23. This line lacks both connective tissue and 
mucosal mast cells owing to Cre-mediated eradication of the entire mast cell lineage. In 
addition to mast cells, carboxypeptidase A3 (Cpa3) is weakly expressed in hematopoietic 
progenitors and splenic basophils23.
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We verified mast cell deficiency in skin and pancreas of Cpa3Cre/+, as compared to wild-
type mice (Fig. 4a,b). We then analyzed mast cell infiltration and PanIN/PDAC formation 
in KF mice with and without Cpa3Cre/+ (Fig. 4c-g). Staining with toluidine blue and 
immunofluorescent staining of the high affinity IgE receptor FcεRI revealed the absence of 
mast cells in PanIN and PDAC lesions of Pdx1-Flp;FSF-KrasG12D/+;Cpa3Cre mice, whereas 
KF controls frequently showed mast cell infiltration (Fig. 4c,d,f,g). To investigate the role 
of mast cells in PDAC initiation, we analyzed mice deficient and proficient in mast cells at 9 
months old, when all grades of PanIN are present in the KF model (Figs. 1c and 4e). The 
number and grade of PanIN were the same, regardless of the presence of mast cells (Fig. 
4e). We also analyzed some mice at age 12 months. These showed sporadic occurrence of 
invasive PDAC, again regardless of whether mast cells were present (Fig. 4f,g).
Mast cells are therefore dispensable for PDAC formation. Previous reports have, however, 
described dramatically altered tumor development and growth in mast cell–deficient 
hypomorphic Kit-mutant mice (e.g. KitW-sh), or mice treated with cromolyn, a mast cell 
stabilizer20,24,25. We investigated expression of the Kit proto-oncogene during pancreatic 
carcinogenesis and frequently observed Kit expression in PanIN and PDAC cells by 
immunohistochemistry (Supplementary Fig. 10f,g). Kit expression in pancreas was also 
analyzed by lineage tracing with a tamoxifen-inducible KitCreERT2 knock-in mouse line26, 
revealing that Kit marks a distinct pancreatic cell population (Supplementary Fig. 10h). 
The R26mT-mG-Cre reporter indicated no leaky Cre activity in the absence of tamoxifen.
These data indicate that hypomorphic Kit mutations may contribute to the altered tumor 
phenotype of mast cell–deficient models in a mast cell–independent manner23.
To gain insight into gene expression changes associated with mast cell deficiency, we 
performed mRNA expression profiling of pancreatic tumors and obtained a statistically 
significant gene expression signature of mast cell deficiency in Pdx1-Flp;FSF 
KrasG12D/+;Cpa3Cre/+ mice using “gene set enrichment analysis” (GSEA) (Normalized 
Enrichment Score: -1.5837048; Nominal P-value: 0.008152174; False Discovery Rate 
(FDR) q-value: 0.0096; see also Supplementary Results). mRNA expression analysis of 
genes relevant to PDAC revealed no significant (P < 0.05) changes due to mast cell ablation, 
except for C-X-C motif chemokine 13 (Cxcl13), fibroblast growth factor 21 (Fgf21) and 
interleukin 2 receptor gamma (Il2rg) (Supplementary Fig. 11a,b and data not shown). Only 
155 probe sets (0.44%), corresponding to 108 annotated genes, showed significantly (P < 
0.05) different changes (>2-fold) in mRNA expression between mast cell deficient and 
proficient pancreatic tumors (Supplementary Fig. 11c). In addition to the aforementioned 
three gene products, cathepsin E and the mucin Muc5ac have been linked to pancreatic 
disease (Supplementary Fig. 11d). Thus, cancer-relevant pathways are not broadly affected 
by mast cell deficiency, corroborating our finding that mast cells do not influence PDAC 
development.
DISCUSSION
Breakthroughs in cancer research, such as genomic analysis and high-throughput drug and 
genetic screening, are providing a wealth of resources and large, complex data sets. 
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Understanding and interpreting the biological and clinical relevance of these resources is a 
significant challenge but holds the promise of breakthrough treatments for particularly 
difficult conditions, such as PDAC.
What has so far made it difficult to take full advantage of these developments is a means of 
realistically modeling and manipulating the developing tumor entity and its 
microenvironment. This is vital for the identification and assessment of candidate 
therapeutic targets. We have generated, characterized and validated a next-generation DRS 
that enables sequential genetic manipulation of PanIN and PDAC cells and the host on a 
genome-wide scale in vivo. Combining the Flp-FRT recombination system for tumor 
initiation with the ‘universal’ Cre-loxP system for secondary genetic manipulation provides 
researchers with new opportunities to model, manipulate and investigate diverse aspects of 
malignant tumors in whole animals. This includes rigorous genetic analysis of (i) genetic 
alterations in multistep carcinogenesis, (ii) tumor cell subpopulations such as cancer stem 
cells, (iii) the tumor microenvironment, (iv) immune cell subpopulations, (v) the metastatic 
niche of host organs, (vi) therapeutic targets and (vii) resistance mechanisms (Fig. 5).
The PDAC stroma supports tumor growth and mediates drug resistance and is clearly 
relevant to future therapies12,14. It is therefore important to understand the biology of the 
different stromal subcomponents. To demonstrate the utility of the DRS-based PDAC model 
as a means of targeting the tumor microenvironment, we investigated the role of mast cells 
and showed that they are dispensable for PDAC initiation and progression (Supplementary 
Results).
Besides evaluating stromal subpopulations, the DRS-based PDAC model enables sequential 
mutagenesis within tumor-initiating cells or precursor PanIN lesions, as previously used to 
study p53 loss during sarcomagenesis27. It also allows rigorous genome-wide testing of 
tumor cell–intrinsic therapeutic targets. Synthetic lethal interaction partners of oncogenic 
Kras28 and multiple novel candidate genes and pathways identified via genome-wide small 
hairpin RNA– and transposon-based forward genetic screens and next-generation 
sequencing28–30 demonstrate impressively that potential treatment targets are available. 
These await rigorous genetic validation in vivo.
We demonstrated secondary genetic targeting, thus mimicking therapeutic interventions, 
using a floxed Pdpk1 mouse line and a latent DTA allele as proof of concept. Our model thus 
provides an ideal complement for genome-wide mouse embryonic stem cell repositories and 
mutant lines with Cre-inducible somatic inactivation of every gene, enabling genome-wide 
target validation31. The synergistic power of these developments will spur the field.
Two groups have generated transgenic GEMMs that allow tetracycline (TET)-inducible 
expression of oncogenic Kras in pancreas and its time-specific inactivation32,33. These 
showed that continuous oncogenic Kras activity is essential for tumor maintenance32,33. 
Combined with Cre-loxP, Flp-FRT and other recombination systems such as Dre-rox, these 
TET-Kras mice, as well as novel embryonic stem cell–based PDAC models34, will further 
increase the possibilities of modeling and manipulating PDAC cells and their 
microenvironment.
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In summary, we developed a next-generation Flp-FRT–based spontaneous model of Kras-
driven stroma-rich PDAC that recapitulates major hallmarks of human PDAC with minimal 
extrapancreatic disease. The use of secondary modifications allows genetic dissection of the 
native biology of PDAC tumors and their associated stroma and rigorous genetic validation 
of candidate therapeutic targets. The DRS model can thus contribute directly to the 
development of new therapeutic strategies. Generation of tissue-specific Flp driver lines or 
viral Flp delivery27,35 will allow spatial and temporal control of gene expression in various 
cancer models. The DRS approach is highly versatile with wide applicability and has the 
potential to significantly advance cancer research.
ONLINE METHODS
Materials
All cell culture reagents were obtained from Invitrogen (Groningen, The Netherlands). 
Primers were made by MWG (Ebersberg, Germany) and restriction endonucleases obtained 
from New England Biolabs (Mannheim, Germany). The E. coli strains TOP10 and Stbl3 
(Invitrogen, Groningen, The Netherlands) were used for transformation and plasmid 
amplification. 4-Hydroxytamoxifen (H6278) and peanut oil (P2144) were purchased from 
Sigma (Deisenhofen, Germany).
Mouse strains and tumor models
LSL-KrasG12D/+2, Pdx1-Cre2, LSL-Trp53R172H/+16, Trp53frt/+35, Trp53lox/+36, Trp53Δ/+37, 
LSL-R26Tva-i-lacZ/+4, R26mT-mG/+38, FSF-R26hpAP/+39, Pdpk1lox/+40, Cpa3Cre/+23, 
KitCreERT2/+26, R26Flpo/+41 and LSL-R26DTA/+42 have been described previously. Unless 
otherwise stated, animals were on a mixed C57Bl/6;129S6/SvEv genetic background. The 
strains were interbred to obtain mice with activation of oncogenic KrasG12D in the pancreas 
as previously described10. Age- and sex-matched randomized animals were used as 
indicated and no animals were excluded from analyses. All animal studies were conducted 
in compliance with European guidelines for the care and use of laboratory animals and were 
approved by the Institutional Animal Care and Use Committees (IACUC) of Technische 
Universität München, Regierung von Oberbayern and UK Home Office.
Construction of the Pdx1-Flp transgenic line
To generate the Pdx1-Flp construct, a 6.3 kb fragment containing the Pdx1 promoter from 
pKSpdx-1SalI (#571, a kind gift from C. Wright; see Supplementary Figure 1a) was 
ligated to the codon optimized Flp-o cDNA (a kind gift from P. Soriano; Addgene plasmid # 
13792;41). The start codon of the Flp-o cDNA was directly fused to the ATG start codon of 
the Pdx1 gene. The human beta globin polyadenylation signal sequence was ligated 3’ of the 
Flp-o expression construct. The 8.1 kb insert was released from pBluescript by SalI-PmeI 
digestion and was used for pronuclear injection into C57BL/6 zygotes (Polygene, Rümlach, 
Switzerland).
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Construction of targeting vectors and generation of FSF-R26CAG-CreERT2 and FSF KrasG12D 
knock-in mouse lines
Rosa26 targeting by a knock-in strategy was performed on the basis of plasmid pROSA26–1 
as previously described4. A targeting vector containing a CAG promoter and a FRT-flanked 
transcriptional and translational stop cassette (FRT-stop-FRT; FSF) with a neomycin 
resistance gene 5’ of the CreERT2 expression cassette was generated by standard cloning 
procedures (Supplementary Figure 2a). The targeting vector was linearized and 
electroporated into 129S6/SvEv embryonic stem (ES) cells. Cells were selected with 200 μg 
ml–1 Geneticin, and correctly targeted homologous recombined clones identified by PCR as 
described4. Correct recombination and single copy insertion was verified by long range and 
quantitative PCR, respectively. Germ-line transmission was achieved in 2/2 clones 
harboring the targeted allele. A three-primer PCR strategy (Supplementary Figure 2b) was 
used to genotype FSF-R26CAG-CreERT2 animals as described4.
To generate a novel tamoxifen-inducible CreERT2 deleter mouse line (termed 
R26CAG-CreERT2), which ubiquitously expresses CreERT2, we deleted the FRT-flanked 
transcriptional stop cassette in FSF-R26CAG-CreERT2 animals using the R26Flpo/+41 deleter 
line.
To construct the FSF-KrasG12D targeting vector, we used a Kras genomic clone, amplified 
the long and short arm of the Kras targeting vector by PCR and introduced a codon 12 
aspartic acid mutation into exon 2 by site-directed mutagenesis. Finally, a FSF cassette with 
a splice acceptor 3’ of the first FRT recombination site and a promoterless neomycin 
resistance cassette was introduced into the first intron of the Kras targeting vector 
(Supplementary Figure 5a). All constructs were verified by sequencing. We electroporated 
the PacI linearized targeting vector into 129S6/SvEv ES cells and selected appropriately 
targeted clones with 200 μg ml–1 Geneticin. Homologous recombined clones were identified 
by PCR and correct recombination and single copy insertion was verified by long range 
PCR and quantitative PCR, respectively. Two clones were injected into blastocysts 
(Polygene, Rümlach, Switzerland). Germ-line transmission was achieved in 2/2 clones 
harboring the targeted allele. A three-primer PCR strategy (Supplementary Figure 5b) was 
used to genotype animals.
Fluorescence stereomicroscopy and quantification of metastasis frequency
Macroscopic analysis of mouse tissues, PDAC and metastases was performed using a Zeiss 
Stemi 11 fluorescence stereomicroscope. At necropsy, all abdominal organs and the lungs 
were investigated macroscopically for metastases as described17,43. For microscopic 
quantification of metastases at least three series of sections (100 μm between the different 
series) of paraffin embedded lungs and livers of 20 mice per genotype with PDAC were 
prepared, H&E stained and investigated for the presence of metastases by an examiner 
blinded to the genotype of the animals.
Fluorescence in situ hybridization (FISH)
Metaphase spreads were prepared from splenocytes using standard protocols and 
fluorescence in situ hybridization was performed as described44. Probes specific for the Flp 
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transgene were amplified using GenomePlex® Complete Whole Genome Amplification 
(WGA) kit (WGA2, Sigma) and labeled directly with ChromaTide Texas Red dUTP 
(Invitrogen) using GenomePlex® WGA Reamplification Kit (WGA3, Sigma) and custom-
made dNTP mixture. Probes were then denatured for 10 min at 65 °C and preannealed for 
approximately 30 – 45 min at 37 °C. Slides were prepared one week in advance, to age 
metaphases at RT with a desiccant. Slides were then pretreated in prewarmed 2 × SSC and 
pepsin (75 μl of 1% pepsin in 50 ml of 0.01 M HCl) at 37 °C for 5 min each. Slides were 
washed 3 times in 2 × SSC for 3 min, and then treated for 10 min in formaldehyde fixative 
(1.25 ml of formaldehyde, 40% w/v and 2.5 ml of 1 M MgCl2, 50 mM MgCl2 in PBS) at 
RT. Slides were washed 3 times in 2 × SSC for 3 min, passed through an ethanol series and 
air dried. Slides were then denatured in 70% formamide, 2 × SSC for 1 min 30 s, at 63 °C 
and passed again through an ethanol series and air dried. Denatured preannealed probes 
were added to the slides, covered with coverslips, sealed with Fixogum rubber cement 
(Marabu) and incubated overnight at 37 °C. To remove unbound probes, slides were 
subjected to post-hybridization washes and mounted in SlowFade (Invitrogen) with DAPI 
(4,6 diamidino-2-phenylindole), overlayed with coverslip and sealed with nail varnish. 
Metaphases were scanned using an epifluorescence microscope equipped with a CCD 
camera and narrow band-pass filters. Images were captured using the SmartCapture software 
(Digital Scientific, UK) and metaphases were karyotyped using the SmartType Karyotyper 
software (Digital Scientific).
Generation and culture of primary mouse PDAC cell lines
Primary dispersed mouse pancreatic cancer cells were established and cultivated as 
previously described43. PDAC cells were cultured in DMEM supplemented with 10% FCS 
and 0.1 or 0.5 μM 4-hydroxytamoxifen or vehicle (ethanol) to delete loxP flanked sequences 
in vitro. Cell proliferation was quantified by cell counting on consecutive days. All cell lines 
were authenticated by genotyping and tested for mycoplasma contamination.
Tamoxifen treatment of mice
Mice were fed with tamoxifen-containing chow (400 mg tamoxifen citrate kg–1 chow; 
CreActive TAM400, LASvendi, Soest, Germany) for 2 or 4 weeks to activate CreERT2.
High-resolution ultrasound
Mice were screened for tumors by abdominal palpation. Palpable tumors were verified by 
high-resolution ultrasound (Vevo 2100, VisualSonics). Animals with average tumor 
diameters greater than 5 mm were enrolled in the treatment study as described17. Tumor 
volumes were determined by automated three-dimensional (3D) B-mode imaging along the 
entire length of the tumor (VisualSonics). Reconstructed three-dimensional ultrasound 
imaging data sets were analyzed and tumor volumes were quantified using the integrated 
Vevo 2100 software package (VisualSonics) by an examiner blinded to the genotype of the 
animals. Macroscopic tumor perfusion was analyzed using the Doppler mode of the Vevo 
2100 system.
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Quantitative reverse-transcriptase PCR
Total RNA was isolated from tissues using the RNeasy kit (Qiagen, Hilden, Germany) 
following the manufacturer's instructions and reverse transcribed (Invitrogen). Quantitative 
mRNA analyses were performed using real-time PCR analysis (TaqMan, PE Applied 
Biosystems, Norwalk, CT) and QuantiTect Primer Assays (Qiagen) as previously 
described45.
Laser capture microdissection and DNA extraction
PanIN lesions and normal acini from 8 μm thick, dewaxed, hematoxylin and eosin stained 
formalin fixed paraffin embedded tissue sections were microdissected using a P.A.L.M. 
laser capture microdissection system (Zeiss, Göttingen, Germany) as described previously46. 
DNA was isolated from the microdissected cells using the QIAamp DNA Micro Kit 
(Qiagen, Hilden, Germany).
Histochemistry and immunohistochemistry
For histopathology, mouse tissue specimens were fixed in 4% buffered formalin overnight, 
embedded in paraffin and sectioned (2.5 μm thick). Quantification and grading of mouse 
ADM and PanIN lesions was performed on three sections per mouse and 3 mice per time 
point according to the established nomenclature for the grading of PanIN lesions in mice47. 
The examiner was blinded to the genotype of the animals. Alcian blue staining was 
performed on paraffin embedded tissue sections using aqueous alcian blue solution (pH 2.5). 
Sections were counterstained with nuclear fast red, as previously described17. Toluidine blue 
staining of mast cells was performed using an aqueous toluidine blue staining solution (pH 
2.0) for 10 min (all staining solutions from Sigma). For immunodetection, formalin-fixed 
paraffin-embedded tissue sections were dewaxed, rehydrated and placed in a microwave (10 
min, 600 watt) to recover antigens. Sections were incubated with primary c-Kit (C-19; 
sc-168; 1:50; Santa Cruz Biotechnology, Santa Cruz, CA), p53 (NCL-p53-CM5p; rabbit, 
1:400; Novocastra/Leica Mikrosysteme, Wetzlar, Germany) and Pdpk1 (Pdk1, #3061; 
rabbit, 1:50; Cell Signaling Technology, Danvers, MA) antibodies followed by a secondary 
antibody conjugated to biotin (Vector Laboratories, Burlingame, CA).
β-galactosidase staining
β-galactosidase staining of cryosections was performed as described previously4. 
Counterstaining was carried out with eosin or nuclear fast red.
Alkaline phosphatase (AP) staining
Cryosections were post-fixed in 4% paraformaldehyde in PBS for 10 min at 4 °C. After 
rinsing with cold PBS, sections were incubated at 70 °C in preheated PBS for 30 min, 
followed by incubation in AP detection buffer (100 mM NaCl, 100 mM Tris-HCl pH 9.5, 50 
mM MgCl2) for 30 min. Sections were subsequently placed in AP staining solution (AP 
detection buffer with 0.8 mg ml–1 nitroblue tetrazolium (NBT), 0.1 mg ml–1 5-bromo-4-
chloro-3-indolyl phosphate dimethylformamide (BCIP), 0.01% sodium deoxycholate, 0.02% 
NP-40, and 0.5 mM levamisole) at room temperature overnight. Once color development 
was complete, sections were counterstained with nuclear fast red or eosin.
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Immunofluorescence staining
Mouse tissues were fixed in 4% buffered formalin for 2 h, dehydrated in sucrose solution at 
4 °C (15% sucrose in PBS for 4 h; 30% sucrose in PBS overnight) and embedded in Tissue-
Tek® (Sakura, Torrance, CA) before being rapidly frozen in liquid nitrogen. 20 μm thick 
frozen sections were post-fixed for 1 min in 4% buffered formalin, washed twice in PBS and 
incubated for 1 h in PBS with 3% (w/v) bovine serum albumin (BSA), 1% (w/v) Saponin 
and 1% (v/v) Triton-X 100. Subsequently, slides were incubated for 48 h at 4 °C in the dark 
with primary antibodies: Kit (M14; goat, 1:100; sc-1494, Santa Cruz Biotechnology, Santa 
Cruz, CA), alpha-amylase (A8273; rabbit, 1:100; Sigma-Aldrich), insulin (C27C9; rabbit, 
1:100; #3014, Cell Signaling Technology), CK19 (ab52625; rabbit, 1:75; abcam, 
Cambridge, UK), or PE labeled FcεRI alpha (#12-5898-82; hamster, 1:100; eBioscience, 
Frankfurt, Germany) as described26. Kit, α-amylase, insulin and CK19 antibody stained 
slides were incubated in the dark with secondary antibody Alexa Fluor® 488 donkey anti-
goat (1:100, Invitrogen), DyLight® 680 goat anti-rabbit IgG (H+L) (1:100; #5366), or 
DyLight® 800 goat anti-rabbit IgG (H+L) (1:100; #5151, both from Cell Signaling 
Technology). Nuclei were counterstained in selected sections with TOPRO®-3-iodide 
(1:1000, Invitrogen) for 2 h at RT. Selected sections were additionally counterstained with 
Alexa Fluor® 594 labeled phalloidin (1:250, Invitrogen) to visualize actin filaments and thus 
cell morphology. After three rinses in PBS, slides were mounted with Vectashield Mounting 
Medium (Vector Laboratories, Burlingame, CA).
Confocal laser-scanning microscopy
Cryosections were examined by confocal laser scanning confocal microscopy (LSM) with a 
Zeiss LSM 510 Axiovert 100 microscope (Zeiss, Oberkochen, Germany) with a ×20/0.5 air 
and a ×40/1.3 oil-immersion objective (optical section thickness 4.4 mm) as described26. 
Images (single optical sections and z-stacks, z-step size 0.5 mm) with a frame size of 1,024 
× 1,024 pixels and an image size of 225 × 225 mm (×40/1.3 objective, Zeiss), or 450 × 450 
mm (×20/0.5 air objective, Zeiss) were collected. Images were merged and converted with 
Zeiss LSM 510 software.
Staining and counting of skin mast cells
Staining of skin mast cells was performed as described26. In brief, ears of the respective 
animals were separated into a ventral and dorsal half and fixed in 1% buffered formalin 
overnight at 4 °C. After incubation for 1 h at RT in 1% BSA in PBS, mast cells were stained 
with avidin-Texas Red (1:500, Invitrogen) as described26. Nuclei were counterstained with 
TOPRO®-3-iodide. For mast cell-counting, the ears of at least 3 mice per genotype and 10 – 
15 fields of view of each animal were analysed by LSM using the Zeiss LSM 510 
microscope with a × 20/0.5 air objective. The examiner was blinded to the genotype of the 
animals.
RNA expression analyses
RNA extraction and microarray expression analyses were performed as recently 
described43,48. In brief, total RNA was prepared using RNeasy Kit (Qiagen) and processed 
with the Ambion WT expression kit (Applied Biosystems). Purified single-stranded cRNA 
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was fragmented and labeled by using the GeneChip WT terminal labeling kit (Affymetrix, 
Santa Clara, CA) and hybridized onto Affymetrix GeneChip Mouse Gene 1.0 ST Array. 
Calculation of expression values was done by taking the mean of all perfect match probes 
for each probeset. The expression dataset was quantile normalized and each probeset was 
assessed for differential expression with standard Student's t test. Resulting P-values are 
corrected for the number of tests (48107) with the method by Benjamini & Hochberg49. 
Gene set enrichment analysis (GSEA) was performed with GSEA software (Broad Institute, 
MIT, MA; www.broadinstitute.org)50. Genes down-regulated > 2 fold in mast cell-deficient 
tissues (peritoneum and ear)23 were defined as gene set “Mast_cell_deficiency”. P-values < 
0.05 with a false discovery rate (FDR) q-value < 0.05 (5%) and a family-wise error rate 
(FWER) P-value < 0.05 were considered to be statistically significant. Heatmaps for the 
expression levels of selected genes were assembled with the GenePattern software package 
(Broad Institute). Microarray data are available in the EMBLEBI ArrayExpress database 
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-2551.
Data analysis
Unless otherwise indicated, all data were determined from at least three independent 
experiments and expressed as mean values ± s.e.m. Sample size was calculated using 
GraphPad StatMateSoftware 2.00 (GraphPad Software, Inc.; La Jolla, CA). Statistical 
comparisons between data sets were made with analysis of normality and variance, followed 
by a two-sided unpaired Student's t test. A Bonferroni correction of the P values was 
performed for pair wise multiple testing. Fisher's exact test was performed by using 
STATXACT 4.0.1 software (Cytel Software, Cambridge, MA) as described51. Values of P < 
0.05 were considered to be statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Pdx1-Flp–activated expression of oncogenic KrasG12D induces premalignant PanIN and 
PDAC. (a) Left, genetic strategy to activate oncogenic Kras in the pancreas using the Flp-
FRT (top) and the Cre-loxP (bottom) recombination system. Right, representative alcian 
blue and hematoxylin and eosin (H&E) stained sections of different grades (1-3) of 
pancreatic intraepithelial neoplasia (PanIN) and invasive PDAC of male and female Pdx1-
Flp;FSFKrasG12D/+ (top) and Pdx1-Cre;LSL-KrasG12D/+ (bottom) mice. (b) Genetic 
strategy to induce oncogenic KrasG12D and human placental alkaline phosphatase (hpAP) 
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reporter gene expression in the Pdx1-Flp lineage (left). Representative alkaline phosphatase 
staining (purple) of the indicated grades of PanIN lesions and PDAC cells in male and 
female Pdx1-Flp;FSF-KrasG12D/+;FSF-R26hpAP/+ mice (right). (c) Quantification of acinar 
to ductal metaplasia (ADM) and PanIN progression (from PanIN grade -1A (flat epithelial 
lesion), -1B (papillary lesion), -2 (lesion with nuclear abnormalities) to PanIN grade -3 
(carcinoma in situ)) as a percentage of total lesions in Pdx1-Flp;FSF-KrasG12D/+ and Pdx1-
Cre;LSLKrasG12D/+ mice (error bars, s.e.m.; n = 3 representative slides from three mice per 
time point and genotype). (d) Kaplan-Meier survival curves of Pdx1-Flp;FSF-KrasG12D/+ 
and Pdx1-Cre;LSL-KrasG12D/+ mice. (e) Occurrence of extrapancreatic tumors in KF mice. 
Scale bars, 50 μm.
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Figure 2. 
Secondary genetic manipulation of established KrasG12D-induced PanIN lesions and PDAC 
cells in the Pdx1-Flp lineage. (a) Genetic strategy to induce EGFP expression in the Flp 
lineage by tamoxifen-mediated activation of CreERT2. (b) Representative confocal 
microscopic images of tdTomato (red, non–Cre-recombined cells) and Cre-induced EGFP 
(green) expression in the pancreas and indicated PanIN lesions of tamoxifen- (+TAM) and 
vehicle-treated (–TAM) male and female mice. Arrowheads indicate highest-grade PanIN 
lesions; arrows indicate stromal cells. Nuclei were counterstained with TOPRO-3 (blue). (c) 
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Genetic strategy to recapitulate human multistep carcinogenesis by time-specific p53 
inactivation. (d) Top, schematic of tamoxifen treatment protocol. Bottom, representative 
alcian blue (blue) and H&E-stained pancreatic tissue sections of randomized tamoxifen-
treated Pdx1-Flp;FSF-KrasG12D/+;FSF-R26CAG-CreERT2/+;Trp53lox/lox mice (+TAM) and 
untreated age- and sex-matched littermate controls (–TAM). n = 3 mice per group. Bottom, 
immunohistochemical p53 staining demonstrates loss of p53 expression in TAM-treated 
tumors but not in untreated controls. (e) Genetic strategy to induce lacZ expression by 
tamoxifen-mediated CreERT2 activation (left). Right, representative β-galactosidase staining 
(n = 3 representative slides from three mice) shows expression of lacZ in PanIN lesions and 
PDAC, but not in desmoplastic stroma of tamoxifen-treated male and female Pdx1-
Flp;FSFKrasG12D/+;FSF-R26CAG-CreERT2;LSL-R26Tva-i-lacZ mice. Scale bars, 50 μm.
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Figure 3. 
Validation of therapeutic targets in vivo by Cre-induced time-specific Pdpk1 inactivation or 
DTA-mediated tumor cell depletion. (a) Genetic strategy to delete Pdpk1 in established 
PanIN lesions by time-specific tamoxifen-mediated CreERT2 activation. (b) Top, schematic 
of tamoxifen (TAM) treatment protocol. Bottom, representative macroscopic view (left) and 
weight (right) of pancreata from TAM-treated homozygous conditional Pdpk1-knockout 
mice (Pdpk1lox/lox) and age- and sex-matched TAM-treated heterozygous controls 
(Pdpk1lox/+). Visible tumors are outlined in white. WT, wild type. Data represent mean ± 
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s.e.m; n = 3 female mice per genotype; *P = 0.0148, Student's t test. (c) Representative 
pancreatic sections of TAM-treated Pdpk1lox/+ control (top) and Pdpk1lox/lox (bottom) mice 
stained with standard H&E or alcian blue (AB) to visualize mucinous PanIN lesions stained 
in blue and immunohistochemical Pdpk1 staining. (d) Absolute quantification of different 
grades of PanIN lesions (grade −1A, flat epithelial lesion; grade −1B, papillary lesion; grade 
−2, lesion with nuclear abnormalities; grade −3, carcinoma in situ) in 9-month-old sex-
matched TAM-treated mice with genotypes as indicated (mean and s.e.m.; n = 3 female 
mice per genotype; 3 representative slides per mouse; ***P < 0.001, **P < 0.01, Student's t 
test; ∆P = 0.05, Fisher's exact test). (e) Top, genotyping strategy to detect Pdpk1 alleles. 
Bottom, PCR analysis of nonrecombined Pdpk1lox/lox DNA from a mouse without Cre 
expression, recombined pancreatic tissue from a Ptf1aCre/+;LSL-KrasG12D/+;Pdpk1lox/lox 
(Pdpk1Δ/Δ;17) mouse (positive control for recombined allele) and microdissected PanIN 
lesions from TAM-treated Pdpk1lox/lox mice. (f) Genetic strategy to induce DTA expression 
in established PDAC by tamoxifen-mediated CreERT2 activation. (g) Tumor growth was 
monitored by high-resolution ultrasound in sex-matched DTA and control mice with mean 
tumor diameters >5 mm before (day 0) and 4 and 7 d after treatment with tamoxifen 
(+TAM). Macroscopic tumor perfusion was evaluated by Doppler ultrasound. Visible 
lesions are outlined in white; numbers (bottom right corner) indicate tumor burden as 
determined by automated three-dimensional B-mode imaging. (h) Quantification of tumor 
volume in TAM-treated DTA (n = 4) and control (Ctrl, n = 3) mice. (i) Representative 
macroscopic view of pancreas from TAM-treated DTA (top) and control (bottom) mouse. (j) 
Representative H&E stains of TAM-treated DTA (top) and control (bottom) mouse. Scale 
bars, 50 μm.
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Figure 4. 
Mast cells are dispensable for PDAC development. (a) Representative confocal microscopic 
images of skin whole-mounts of male Cpa3Cre/+ and littermate control (Ctrl) mice on a 
C57BL/6 genetic background. Mast cells were stained with avidin-TexasRed (red) and 
nuclei were counterstained with TOPRO-3 (blue). (b) Quantification of skin (left) and 
pancreatic (right) mast cells in male and female Cpa3Cre/+ and control mice (mean, ± s.e.m.; 
10–15 fields of view per animal; each dot in the graph represents one mouse). (c) Genetic 
strategy to eradicate mast cells in the KF model by Cre recombinase expression using 
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Cpa3Cre/+ mice (left). Representative images of toluidine blue–stained metachromatic mast 
cells (purple) in PanIN-bearing pancreata of male and female KF (top) and mast cell-
depleted Pdx1-Flp;FSF-KrasG12D/+;Cpa3Cre/+ (bottom) mice (n = 3 animals per genotype). 
(d) Quantification of tumor-infiltrating mast cells in 9-month-old PanIN-bearing male and 
female mice with genotypes as indicated (mean ± s.e.m.; 15 fields of view per animal). (e) 
Absolute quantification of ADM and different grades of PanIN lesions in 9-month-old male 
and female Pdx1-Flp;FSF-KrasG12D/+;Cpa3Cre/+ (n = 3) and Pdx1-Flp;FSF-KrasG12D/+ (n 
= 4) mice (mean and s.e.m.; three representative slides per mouse). (f) Representative H&E 
and toluidine blue staining of tissue sections from 12-month-old male Pdx1-Flp;FSF-
KrasG12D/+ (top) and Pdx1-Flp;FSF-KrasG12D/+;Cpa3Cre/+ mouse with established PDAC 
(three representative slides per mouse). (g) Representative immunofluorescence staining of 
FcεRI (red) in mast cells in PDAC-bearing male Pdx1-Flp;FSF-KrasG12D/+ (top) and Pdx1-
Flp;FSF-KrasG12D/+;Cpa3Cre/+ (bottom) mouse (three representative slides per mouse). 
Nuclei are counterstained with TOPRO-3 (blue). Scale bars, 50 μm.
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Figure 5. 
Applications of DRS. Stroma-rich PDAC tumors can be induced by Pdx1-Flp– mediated 
activation of an FRT-stop-FRT (FSF) silenced oncogenic KrasG12D allele in the pancreas. 
Middle, secondary genetic manipulation of tumor cells in the Flp lineage can be achieved by 
a FSF-silenced latent CreERT2 allele (FSF-R26CAG-CreERT2). CreERT2 can be activated by 
tamoxifen treatment at any time point during tumor formation and progression to recombine 
floxed sequences. In this way it is possible to model and analyze multistep carcinogenesis, 
manipulate tumor subpopulations, validate therapeutic targets in established tumors and 
analyze resistance mechanisms by genetic approaches. The use of various Flp driver lines or 
a Flp-expressing virus allows expression of oncogenic KrasG12D or any other Flp-FRT-
regulated oncogene or tumor suppressor in various different tissue and cell types. Left, use 
of a CreERT2 deleter allele, which is expressed from the Rosa26 locus under the control of 
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the CAG promoter in all cells of the body, allows whole-organism, time-specific deletion of 
a target or pathway, making it possible to mimic drug treatment and thus evaluate its value 
as a drug target for therapy of established PDAC. Right, Cre driver lines and expression 
models can be used to target subpopulations of the tumor microenvironment, such as 
fibroblasts (orange), stellate cells (yellow), endothelial cells, pericytes, adipocytes and mast 
cells (blue), as well as other immune cells. In addition, metastasis target organs and the 
metastatic niche and other host factors, tissues and cells can be genetically manipulated.
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